PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case
This article was originally published in The Pink Sheet Daily
Executive Summary
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.